Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Binge-Eating Disorder
Conditions
Binge-Eating Disorder
Trial Timeline
Sep 29, 2017 → Oct 1, 2019
NCT ID
NCT03279731About Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo is a phase 3 stage product being developed by Novo Nordisk for Binge-Eating Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT03279731. Target conditions include Binge-Eating Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03279731 | Phase 3 | Terminated |
Competing Products
3 competing products in Binge-Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |